Evaluation of Patient Registries Supporting Reimbursement Decisions:The Case of Oxaliplatin for Treatment of Stage III Colon Cancer

Background: Access with evidence development has been established for expensive intramural drugs in The Netherlands. The procedure involves a 4-year period of conditional reimbursement. During this period, additional evidence has to be gathered usually through a patient registry. Given the costs and time involved in gathering the data, it is important to carefully evaluate the registry. Objectives: This study aimed to develop a model for the regular evaluation of patient registries during an access with evidence development process and find the optimal length of the registry period. Methods: W... Mehr ...